We are live on ! Find out more
NVCR icon

NovoCure

244 hedge funds and large institutions have $1.19B invested in NovoCure in 2025 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 85 increasing their positions, 79 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

355% more call options, than puts

Call options by funds: $20.4M | Put options by funds: $4.49M

8% more repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 79

7% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 45

1% more funds holding

Funds holding: 242244 (+2)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

2.69% less ownership

Funds ownership: 84.73%82.04% (-2.7%)

30% less capital invested

Capital invested by funds: $1.68B → $1.19B (-$496M)

Holders
244
Holders Change
+2
Holders Change %
+0.83%
% of All Funds
3.2%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
48
Increased
85
Reduced
79
Closed
45
Calls
$20.4M
Puts
$4.49M
Net Calls
+$15.9M
Net Calls Change
-$1.68M

NVCR Hedge Fund Activity: Q3 2025 in Review

244 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q3 2025, worth a combined $1.19B — down 30% from $1.68B a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new NVCR positions and 45 closed out — a net gain of 3 holders — while 85 added to existing stakes and 79 trimmed.

The largest buyer was Soleus Capital Management, adding an estimated $36.6M. The largest seller was Capital World Investors, cutting an estimated $58.6M.

  • 244 institutional investors held NovoCure (NVCR) as of Q3 2025, up from 242 in Q2 2025.
  • Funds reported $1.19B of NovoCure stock for Q3 2025, down 30% quarter-over-quarter.
  • 48 funds opened new NovoCure positions in Q3 2025 and 45 closed out, a net change of +3 holders.
  • The largest NovoCure buyer in Q3 2025 was Soleus Capital Management, an estimated $36.6M added.
  • The largest NovoCure seller in Q3 2025 was Capital World Investors, an estimated $58.6M sold.

Based on aggregated 13F filings for Q3 2025.